APA

Nie K., Zhang Z., Zhang C., Geng C., Zhang L., Xu X., Liu S., Wang S., Zhuang X., Lan K. & Ji Y. (20190625). Osimertinib compared docetaxel-bevacizumab as third-line treatment in EGFR T790M mutated non-small-cell lung cancer. : Lung cancer (Amsterdam, Netherlands).

Chicago

Nie Keke, Zhang Zhongfa, Zhang Chunling, Geng Chuanxin, Zhang Ling, Xu Xiajuan, Liu Shichao, Wang Songping, Zhuang Xingjun, Lan Ketao and Ji Youxin. 20190625. Osimertinib compared docetaxel-bevacizumab as third-line treatment in EGFR T790M mutated non-small-cell lung cancer. : Lung cancer (Amsterdam, Netherlands).

Harvard

Nie K., Zhang Z., Zhang C., Geng C., Zhang L., Xu X., Liu S., Wang S., Zhuang X., Lan K. and Ji Y. (20190625). Osimertinib compared docetaxel-bevacizumab as third-line treatment in EGFR T790M mutated non-small-cell lung cancer. : Lung cancer (Amsterdam, Netherlands).

MLA

Nie Keke, Zhang Zhongfa, Zhang Chunling, Geng Chuanxin, Zhang Ling, Xu Xiajuan, Liu Shichao, Wang Songping, Zhuang Xingjun, Lan Ketao and Ji Youxin. Osimertinib compared docetaxel-bevacizumab as third-line treatment in EGFR T790M mutated non-small-cell lung cancer. : Lung cancer (Amsterdam, Netherlands). 20190625.